Erratum to: ESR1 mutations affect anti-proliferative responses to tamoxifen through enhanced cross-talk with IGF signaling
- PMID: 28439737
- PMCID: PMC9714007
- DOI: 10.1007/s10549-017-4250-4
Erratum to: ESR1 mutations affect anti-proliferative responses to tamoxifen through enhanced cross-talk with IGF signaling
Figures

Erratum for
-
ESR1 mutations affect anti-proliferative responses to tamoxifen through enhanced cross-talk with IGF signaling.Breast Cancer Res Treat. 2016 Jun;157(2):253-265. doi: 10.1007/s10549-016-3829-5. Epub 2016 May 13. Breast Cancer Res Treat. 2016. PMID: 27178332 Free PMC article.
Similar articles
-
ESR1 mutations affect anti-proliferative responses to tamoxifen through enhanced cross-talk with IGF signaling.Breast Cancer Res Treat. 2016 Jun;157(2):253-265. doi: 10.1007/s10549-016-3829-5. Epub 2016 May 13. Breast Cancer Res Treat. 2016. PMID: 27178332 Free PMC article.
-
Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: a supporting role to the epidermal growth factor receptor.Endocrinology. 2005 Nov;146(11):4609-18. doi: 10.1210/en.2005-0247. Epub 2005 Jul 21. Endocrinology. 2005. PMID: 16037379
-
ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer.Breast Cancer Res Treat. 2015 Dec;154(3):543-55. doi: 10.1007/s10549-015-3634-6. Epub 2015 Nov 21. Breast Cancer Res Treat. 2015. PMID: 26590813 Free PMC article. Clinical Trial.
-
Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer.Endocr Relat Cancer. 2005 Jul;12 Suppl 1:S99-S111. doi: 10.1677/erc.1.01005. Endocr Relat Cancer. 2005. PMID: 16113104 Review.
-
Insulin-like growth factors and breast cancer.Biomed Pharmacother. 1995;49(9):415-21. doi: 10.1016/0753-3322(96)82678-3. Biomed Pharmacother. 1995. PMID: 8746077 Review.
Cited by
-
ESR1 alterations and metastasis in estrogen receptor positive breast cancer.J Cancer Metastasis Treat. 2019;5:38. doi: 10.20517/2394-4722.2019.12. Epub 2019 May 4. J Cancer Metastasis Treat. 2019. PMID: 31106278 Free PMC article.
-
Obesity and endocrine therapy resistance in breast cancer: Mechanistic insights and perspectives.Obes Rev. 2022 Feb;23(2):e13358. doi: 10.1111/obr.13358. Epub 2021 Sep 24. Obes Rev. 2022. PMID: 34559450 Free PMC article. Review.
-
Steroid Hormone Receptor and Infiltrating Immune Cell Status Reveals Therapeutic Vulnerabilities of ESR1-Mutant Breast Cancer.Cancer Res. 2021 Feb 1;81(3):732-746. doi: 10.1158/0008-5472.CAN-20-1200. Epub 2020 Nov 12. Cancer Res. 2021. PMID: 33184106 Free PMC article.
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous